Article Text


RNAi-mediated gene silencing in inflammatory monocytes for efficient immuno-intervention in experimental arthritis
  1. Jessy Présumey1,2,
  2. Gabriel Courties1,2,
  3. Louis-Marie Charbonnier1,2,
  4. Virginie Escriou3,4,5,6,
  5. Daniel Scherman3,4,5,6,
  6. Yves-Marie Pers1,2,7,
  7. Pascale Louis-PLence1,2,
  8. Diego Kyburz8,
  9. Steffen Gay8,
  10. Christian Jorgensen1,2,7,
  11. Florence Apparailly1,2,7
  1. 1Inserm, U 844, CHU Saint Eloi University hospital, 80 Rue Augustin Fliche, Montpellier, France
  2. 2University of Medicine, 2 Rue Ecole de Médecine, Montpellier, France
  3. 3Inserm, U 1022, UFR des Sciences Pharmaceutiques et Biologiques, 4 Avenue de l’Observatoire, Paris, France
  4. 4CNRS, UMR8151, Paris, France
  5. 5University of Pharmacy Paris Descartes, Laboratoire de Pharmacologie Chimique, Génétique et Imagerie, Paris, France
  6. 6Ecole Nationale Supérieure de Chimie de Paris, 11 Rue Pierre et Marie Curie, Paris, France
  7. 7CHU Lapeyronie University Hospital, clinical department for osteoarticular diseases, 371 Avenue Gaston Giraud, Montpellier, France
  8. 8Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology, Zurich, Switzerland


Background and objectives The inflammatory monocyte subset is essential in innate immunity but it also contributes to the pathogenesis of many inflammatory and autoimmune disorders including rheumatoid arthritis (RA). Strategies to manipulate this cell subset are thus of importance both scientifically and therapeutically. The pre-B cell colony enhancing factor (PBEF/visfatin/Nampt) is an essential enzyme in the NAD biosynthetic pathway that exerts a key role in the persistence of inflammation through the induction of the expression of the tumour necrosis factor α (TNFα) and IL-6 pro-inflammatory cytokines and is highly expressed in patients with a variety of autoimmune disorders. Here the authors aimed at evaluating whether the precise targeting of PBEF within the inflammatory monocytes could be therapeutically beneficial in RA.

Materials and methods Using an optimised lipid nanoparticle formulated with a PBEF-silencing short interfering (si) RNA or a non-targeting fluorescent siRNA (0,5mg/kg), and systemic administration to collagen-induced arthritic mice (CIA), fluorescence and PBEF expression were monitored in various leucocyte populations including Ly6Chigh monocytes within blood, spleen, and inflamed joints by cytometry. Clinical and biological features of CIA were monitored as previously described.

Results Upon intravenous injection, siRNA-containing liposomes are engulfed by circulating Ly6Chigh inflammatory monocytes and provide efficient down-regulation of PBEF expression as well as of PBEF-induced pro-inflammatory cytokines (TNF and IL-6) in this subset but not in the non-inflammatory subset, leading to decreased number of infiltrating leucocytes in arthritic joints and reduced count of effector T cells. Importantly, when the liposome formulation is optimised for translation to the clinic, siRNA lipoplexes efficiently silence PBEF in human CD14+CD16- inflammatory monocytes ex vivo.

Conclusions Delivery into the inflammatory mouse Ly-6Chigh monocyte population of a siRNA against PBEF is able to reduce molecular and cellular markers of inflammation in a preclinical model of RA, both systemically and locally, inhibiting disease progression.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.